{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:22:09Z","timestamp":1780611729743,"version":"3.54.1"},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,10]]},"DOI":"10.18632\/oncotarget.24694","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T09:08:58Z","timestamp":1523264938000},"page":"18797-18810","source":"Crossref","is-referenced-by-count":11,"title":["Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis"],"prefix":"10.18632","volume":"9","author":[{"given":"Hanan","family":"Goldberg","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenappan","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Sayyid","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(19881101)62:9<2016::AID-CNCR2820620924>3.0.CO;2-G","article-title":"Tumor grade and stage as prognostic variables in upper tract urothelial tumors","volume":"62","author":"Murphy","year":"1988","journal-title":"Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update","volume":"68","author":"Shariat","year":"2015","journal-title":"Eur Urol"},{"key":"3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Crawford","year":"2003","journal-title":"N Engl J Med"},{"key":"4","unstructured":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354:533\u201340."},{"key":"5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Parmar","year":"2011","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-5347(01)66430-9","article-title":"A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Torti","year":"1996","journal-title":"J Urol"},{"key":"9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0022-5347(17)36578-3","article-title":"Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study","volume":"148","author":"Hohenfellner","year":"1992","journal-title":"J Urol"},{"key":"10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000273466","article-title":"Outcome of surgical treatment of patients with upper versus lower urinary tract urothelial carcinoma: stage-by-stage comparison","volume":"84","author":"Kassouf","year":"2010","journal-title":"Urol Int"},{"key":"11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0022-5347(17)38733-5","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience","volume":"142","author":"Jewett","year":"1989","journal-title":"J Urol"},{"key":"12","first-page":"163","article-title":"Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience","volume":"46","author":"Wakeda","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma","volume":"71","author":"Abdollah","year":"2017","journal-title":"Eur Urol"},{"key":"14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Bellmunt","year":"2014","journal-title":"Eur Urol"},{"key":"15","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Siefker-Radtke","year":"2010","journal-title":"Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Matin","year":"2014","journal-title":"Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.urolonc.2016.11.018","article-title":"Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma","volume":"35","author":"Park","year":"2017","journal-title":"Urol Oncol"},{"key":"18","unstructured":"Network NC. Bladder cancer (Version 2.2017). 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Chang","year":"2017","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.urolonc.2016.11.017","article-title":"Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma","volume":"35","author":"Yuh","year":"2017","journal-title":"Urol Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.juro.2014.10.022","article-title":"Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience","volume":"193","author":"Kanao","year":"2015","journal-title":"J Urol"},{"key":"22","article-title":"Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome","volume":"32","author":"Bell","year":"2014","journal-title":"Urol Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000092930","article-title":"Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract","volume":"77","author":"Hong","year":"2006","journal-title":"Urol Int"},{"key":"24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","article-title":"Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration","volume":"182","author":"Kikuchi","year":"2009","journal-title":"J Urol"},{"key":"25","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1002\/cncr.26172","article-title":"Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study","volume":"117","author":"Bigot","year":"2011","journal-title":"Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","article-title":"The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma","volume":"194","author":"Wu","year":"2015","journal-title":"J Urol"},{"key":"27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bju.12801","article-title":"The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study","volume":"116","author":"Margulis","year":"2015","journal-title":"BJU Int"},{"key":"28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.juro.2009.05.040","article-title":"The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival","volume":"182","author":"Ahn","year":"2009","journal-title":"J Urol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.eururo.2011.05.049","article-title":"Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy","volume":"60","author":"Houlgatte","year":"2011","journal-title":"Eur Urol"},{"key":"30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Zigeuner","year":"2012","journal-title":"Eur Urol"},{"key":"31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2005.03.009","article-title":"Upper urinary tract cancer: location is correlated with prognosis","volume":"48","author":"Horenblas","year":"2005","journal-title":"Eur Urol"},{"key":"32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1158\/1055-9965.EPI-04-0522","article-title":"Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States","volume":"14","author":"Thun","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/1097-0142(19910301)67:5<1454::AID-CNCR2820670533>3.0.CO;2-K","article-title":"Rural-urban differences in stage at diagnosis. Possible relationship to cancer screening","volume":"67","author":"Greenberg","year":"1991","journal-title":"Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER Treatment Data With Medicare Claims","volume":"54","author":"Warren","year":"2016","journal-title":"Med Care"},{"key":"35","doi-asserted-by":"crossref","first-page":"S3815","DOI":"10.1002\/cncr.29047","article-title":"Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010","volume":"120","author":"Deorah","year":"2014","journal-title":"Cancer"},{"key":"36","unstructured":"Howlader (ed.), Krapcho (ed.), Miller (ed.), Bishop (ed.), Altekruse (ed.), Kosary (ed.), Yu (ed.), Ruhl (ed.), Tatalovich (ed.), Mariotto (ed.), Lewis (ed.), Chen (ed.), Feuer (ed.), Cronin (ed.). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. 2016. https:\/\/seer.cancer.gov\/csr\/1975_2013\/."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:24:19Z","timestamp":1589041459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":36,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2018,4,10]]}},"alternative-id":["24694","29721162"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24694","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]}}}